SMS. A. Mikailova

S. A. Mikailova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


S. A. Mikailova has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tumor microenvironment of soft tissue sarcomas: emerging opportunities for prognosis and therapy

    by D. R. Makhachev, D. V. Bulanov, R. A. Abramenko, A. R. Gasanov, M. O. Abakarov, A. D. Sanjigoryaeva, A. S. Timryazanskiy, S. A. M, A. V. Uyutnova, I. G. Musapirov, et al.

    Soft tissue sarcomas (STS) are a heterogeneous group of mesenchymal malignancies comprising over 50 histological subtypes. Despite their rarity, these tumors are characterized by aggressive clinical behavior, high metastatic potential, and limited sensitivity to conventional systemic therapies. Accumulating evidence highlights the pivotal role of the tumor microenvironment in STS progression, prognosis, and treatment response. The composition of the immune infiltrate – including tumor-associated macrophages, T and B lymphocytes, and tertiary lymphoid structures – varies substantially across histological subtypes and determines both tumor biology and susceptibility to immunotherapy. The discovery of the prognostic and predictive significance of tertiary lymphoid structures and B-cell infiltration in STS has been one of the most important advances in the field. Immune checkpoint inhibitors have shown clinical activity in select subtypes, including undifferentiated pleomorphic sarcoma, angiosarcoma, and alveolar soft part sarcoma, although overall response rates remain modest. Combination strategies integrating immune checkpoint inhibitors with antiangiogenic agents, chemotherapy, or radiation therapy, as well as adoptive cellular therapies using engineered T-cell receptors, are opening new avenues for personalized treatment. This review systematizes current knowledge on the cellular and molecular composition of the STS microenvironment, its prognostic significance, and emerging therapeutic opportunities.

  • Neuroinflammation as a central link in the pathogenesis of neurodegenerative diseases: molecular mechanisms, clinical correlates, and therapeutic perspectives

    by S. M. Gasanova, A. D. Sandzhigoryaeva, S. A. Mikailova, A. V. Uyutnova, R. F. Safina

    Neuroinflammation is regarded as a central mechanism driving the progression of neurodegenerative diseases, integrating age-associated inflammation, glial dysfunction, blood–brain barrier disruption, mitochondrial stress, and systemic factors. Activation of microglia and astrocytes, involvement of the NLRP3 inflammasome, dysregulation of TREM2 signaling, disturbances in iron and lipid metabolism, as well as the influence of the microbiota and metabolic comorbidities together form a self-sustaining pathological network that exacerbates neuronal loss in Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and multiple sclerosis. Emerging therapeutic strategies include modulation of microglia, inhibition of inflammasome-related cascades, epigenetic approaches, and nanotechnology-based delivery systems for anti-inflammatory compounds; however, their clinical efficacy remains limited. A deeper understanding of the architecture of neuroinflammation opens avenues for the development of targeted and personalized interventions.

  • Nootropics: effects on brain plasticity and cognitive functions

    by S. M. Gasanova, A. D. Sandzhigoriaeva, S. A. Mikailova, A. V. Uyutnova, R. F. Safina

    Nootropics represent a heterogeneous group of substances that affect cognitive functions primarily through modulation of neuroplasticity. Classic agents improve neuronal metabolism and, in experimental models, increase neurotrophin levels, but their clinical efficacy in dementia and other cognitive disorders remains moderate. Psychostimulants provide short-term improvement in attention and performance; however, they do not strengthen long-term plasticity and may adversely affect the developing brain. Herbal and nutraceutical agents exert mild and delayed effects, predominantly manifesting in individuals with mild cognitive complaints or deficits. Despite growing interest in pharmacological cognitive enhancement, convincing evidence of a clinically meaningful improvement in cognitive functions in healthy individuals is lacking, whereas the strongest effects on neuroplasticity continue to be demonstrated by non-pharmacological interventions.